Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Cholestatic liver diseases encompass a wide spectrum of disorders with different causes, resulting in impaired bile flow and accumulation of bile acids and other potentially hepatotoxic cholephils. The understanding of the molecular mechanisms of bile formation and cholestasis has recently improved significantly through new insights into nuclear receptor (patho)biology. Nuclear receptors are ligand-activated transcription factors, which act as central players in the regulation of genes responsible for elimination and detoxification of biliary constituents accumulating in cholestasis. They also control other pathophysiologic processes such as inflammation, fibrogenesis, and carcinogenesis involved in the pathogenesis and disease progression of cholestasis liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Nuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Vitamin D Receptor As an Intestinal Bile Acid Sensor
Makishima, M., Lu, T. T., Xie, W., Whitfield, G. K., Domoto, H., Evans, R. M., Haussler, M. R., & Mangelsdorf, D. J. (2002) · Science · doi:10.1126/science.1070477 · Cited by 1,176
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., Yu, R. T., Shelton, J. M., Richardson, J. A., Repa, J. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509592103 · Cited by 1,164
Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network
Bookout, A. L., Jeong, Y., Downes, M., Yu, R. T., Evans, R. M., & Mangelsdorf, D. J. (2006) · Cell · doi:10.1016/j.cell.2006.06.049 · Cited by 1,015
Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M., & Edwards, P. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109326200 · Cited by 916 · cited 2×
“1).(44) The regulatory role of FXR in secretion of biliary phospholipids (and perhaps even glutathione) may be critical for the protection of hepatocytes’ canalicular membrane as well as the apical membrane of bile duct lining cells against the deter-”
BackgroundGadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut · doi:10.1136/gut.2010.212159 · Cited by 870 · cited 1×
“specific, but were also demonstrated in intestine, where INT-747 reduced intestinal inflammation and permeability in experimental models of colitis.(86) Because bacterial overgrowth and increased intestinal permeability may play an important role in the”
BackgroundFarnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
Wang, Y.-D., Chen, W.-D., Wang, M., Yu, D., Forman, B. M., & Huang, W. (2008) · Hepatology · doi:10.1002/hep.22519 · Cited by 639 · cited 1×
“that FXR-deficient mice showed increased baseline hepatic inflammation and are more prone to LPS-induced liver injury(67,83) suggests a direct anti-inflammatory role of FXR, which has been be explained via direct interference with the nuclear factor kappa-B (NF-kB).(83) Notably, this effect is not only hepatocyte-spec…”
BackgroundFGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
Kir, S., Beddow, S. A., Samuel, V. T., Miller, P., Previs, S. F., Suino-Powell, K., Xu, H. E., Shulman, G. I., Kliewer, S. A., & Mangelsdorf, D. J. (2011) · Science · doi:10.1126/science.1198363 · Cited by 637
Tomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., Stephan, J. P., Tsai, S. P., Powell-Braxton, L., French, D., et al. (2002) · Endocrinology · doi:10.1210/endo.143.5.8850 · Cited by 576
Yang, F., Huang, X., Yi, T., Yen, Y., Moore, D. D., & Huang, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1078 · Cited by 488
Peroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473 · cited 1×
“In HSCs from BDL mice developing biliary cirrhosis, PPARg expression and DNA binding was dramatically reduced, demonstrating that HSC activation is associated with the reductions in PPARg expression.(180)”
BackgroundLysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus
Kremer, A. E., Martens, J. J. W. W., Kulik, W., Ruëff, F., Kuiper, E. M. M., van Buuren, H. R., van Erpecum, K. J., Kondrackiene, J., Prieto, J., Rust, C., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.009 · Cited by 410
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
Kim, I., Morimura, K., Shah, Y., Yang, Q., Ward, J. M., & Gonzalez, F. J. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl249 · Cited by 357
Wagner, M., Halilbasic, E., Marschall, H., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., & Trauner, M. (2005) · Hepatology · doi:10.1002/hep.20784 · Cited by 355 · cited 2×
“However, elevated liver enzymes in these animals point out potential hepatotoxic side effects of the used substances and concentrations, at least under conditions when bile flow is completely blocked.(127) However,”
BackgroundSelf-citationYamamoto, Y., Moore, R., Goldsworthy, T. L., Negishi, M., & Maronpot, R. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1459 · Cited by 350 · cited 1×
“However, CAR activation also plays a key role for liver tumor promotion in phenobarbital-treated mice.(137,138)”
BackgroundLorenzo-Zúñiga, V., Bartolí, R., Planas, R., Hofmann, A. F., Viñado, B., Hagey, L. R., Hernández, J. M., Mañé, J., Alvarez, M. A., Ausina, V., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50116 · Cited by 321
Kremer, A. E., van Dijk, R., Leckie, P., Schaap, F. G., Kuiper, E. M. M., Mettang, T., Reiners, K. S., Raap, U., van Buuren, H. R., van Erpecum, K. J., et al. (2012) · Hepatology · doi:10.1002/hep.25748 · Cited by 291
Abramovitch, S., Dahan-Bachar, L., Sharvit, E., Weisman, Y., Tov, A. B., Brazowski, E., & Reif, S. (2011) · Gut · doi:10.1136/gut.2010.234666 · Cited by 286
Huang, W., Zhang, J., Washington, M., Liu, J., Parant, J. M., Lozano, G., & Moore, D. D. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0520 · Cited by 284
Modica, S., Petruzzelli, M., Bellafante, E., Murzilli, S., Salvatore, L., Celli, N., Di Tullio, G., Palasciano, G., Moustafa, T., Halilbasic, E., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.028 · Cited by 275
Self-citationNuclear Receptors in Liver Disease Δ
Wagner, M., Zollner, G., & Trauner, M. (2011) · Hepatology · doi:10.1002/hep.24148 · Cited by 260
Self-citationCoordinate transcriptional regulation of bile acid homeostasis and drug metabolism
Eloranta, J. J., & Kullak-Ublick, G. A. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.09.019 · Cited by 260
Leuschner, M., Maier, K., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H. H., Ackermann, H., Happ, J., & Leuschner, U. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70351-3 · Cited by 247
COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231 · cited 1×
“Phenobarbital was also given to patients long before the identification of CAR as its molecular target.(115,121,122) Notably, 6,7-dimethylesculetin, a compound present in Yin Chin used in Asia to prevent and treat neonatal jaundice, accelerates bilirubin clearance by activation of CAR.”
MethodRautiainen, H., Kärkkäinen, P., Karvonen, A., Nurmi, H., Pikkarainen, P., Nuutinen, H., & Färkkilä, M. (2005) · Hepatology · doi:10.1002/hep.20646 · Cited by 222
Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04512.x · Cited by 186
Fiorucci, S., Rizzo, G., Antonelli, E., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pruzanski, M., Morelli, A., & Pellicciari, R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084905 · Cited by 183
Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration
Li, Y. T. Y., Swales, K. E., Thomas, G. J., Warner, T. D., & Bishop-Bailey, D. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.152694 · Cited by 171 · cited 1×
“Notably, this effect is not only hepatocyte-specific but also was reported in vascular smooth muscle cells.(84) The anti-inflammatory effects of FXR are further supported by induction of suppressor of cytokine signaling 3 that inhibits STAT3 signaling.”
BackgroundThe Role of Bile and Bile Acids in Bacterial Translocation in Obstructive Jaundice in Rats
Ding, J. W., Andersson, R., Soltesz, V., Willén, R., & Bengmark, S. (2008) · European Surgical Research · doi:10.1159/000129252 · Cited by 133
Bezafibrate treatment: a new medical approach for PBC patients?
Kanda, T., Yokosuka, O., Imazeki, F., & Saisho, H. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-002-1102-7 · Cited by 129
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120
Chen, W.-D., Wang, Y.-D., Zhang, L., Shiah, S., Wang, M., Yang, F., Yu, D., Forman, B. M., & Huang, W. (2010) · Hepatology · doi:10.1002/hep.23390 · Cited by 115
Pregnane X receptor is essential for normal progression of liver regeneration†
Dai, G., He, L., Bu, P., & Wan, Y. Y. (2008) · Hepatology · doi:10.1002/hep.22129 · Cited by 114
Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers
Ritzel, U., Leonhardt, U., Näther, M., Schäfer, G., Armstrong, V. W., & Ramadori, G. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00006-5 · Cited by 94
MAREK, C. J., TUCKER, S. J., KONSTANTINOU, D. K., ELRICK, L. J., HAEFNER, D., SIGALAS, C., MURRAY, G. I., GOODWIN, B., & WRIGHT, M. C. (2005) · Biochemical Journal · doi:10.1042/bj20041598 · Cited by 89 · cited 1×
“In mice, PCN, a potent activator of rodent PXR, inhibited carbon tetrachloride–induced fibrosis in a PXR-dependent manner.(130) In addition, activation of PXR inhibited endotoxin-induced NF-kB activa-”
BackgroundBeilke, L. D., Aleksunes, L. M., Holland, R. D., Besselsen, D. G., Beger, R. D., Klaassen, C. D., & Cherrington, N. J. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023317 · Cited by 73
FXR ligands protect against hepatocellular inflammation via SOCS3 induction
Xu, Z., Huang, G., Gong, W., Zhou, P., Zhao, Y., Zhang, Y., Zeng, Y., Gao, M., Pan, Z., & He, F. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.04.015 · Cited by 71
Shoda, J., Inada, Y., Tsuji, A., Kusama, H., Ueda, T., Ikegami, T., Suzuki, H., Sugiyama, Y., Cohen, D. E., & Tanaka, N. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400132-jlr200 · Cited by 58
Cited by
Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Jia, W., Xie, G., & Jia, W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.119 · Cited by 1,924
Beyond intestinal soap—bile acids in metabolic control
Kuipers, F., Bloks, V. W., & Groen, A. K. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.60 · Cited by 454
Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection
García-Niño, W. R., & Zazueta, C. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.008 · Cited by 274
Cholestatic liver (dys)function during sepsis and other critical illnesses
Jenniskens, M., Langouche, L., Vanwijngaerden, Y.-M., Mesotten, D., & Van den Berghe, G. (2016) · Intensive Care Medicine · doi:10.1007/s00134-015-4054-0 · Cited by 129
Nuclear receptors as therapeutic targets in liver disease: are we there yet?
Rudraiah, S., Zhang, X., & Wang, L. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103209 · Cited by 87
“Depending on the persistence of etiology, disease severity, and duration, hepatic fibrosis may result in liver cirrhosis and hepatocellular or cholangiocellular cancer (81).”
Influential
Metadata
- Authors
- Halilbasic, E., Baghdasaryan, A., & Trauner, M.
- Venue
- Clinics in Liver Disease
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 17
- Issue
- 2
- Pages
- 161-189
- ISSN
- 1089-3261 (ISSN-L)
- OpenAlex
- W1976811057
- Cited by
- 99
- References
- 42
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.